Compare TROO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROO | CRBP |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.5M | 170.3M |
| IPO Year | N/A | N/A |
| Metric | TROO | CRBP |
|---|---|---|
| Price | $1.93 | $8.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $50.29 |
| AVG Volume (30 Days) | 93.3K | ★ 495.7K |
| Earning Date | 12-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,084,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 247.24 | N/A |
| 52 Week Low | $0.49 | $4.64 |
| 52 Week High | $2.62 | $20.56 |
| Indicator | TROO | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 67.65 | 30.77 |
| Support Level | $1.82 | $7.97 |
| Resistance Level | $2.27 | $8.51 |
| Average True Range (ATR) | 0.22 | 0.62 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 59.56 | 8.99 |
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.